Balyasny Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Balyasny Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.99M	Buy	85,756 +79,018	+1,173%	+$3.8M	0.01%	1478
2026 Q1	$348K	Buy	+6,738	New	+$343K	﹤0.01%	2506
2022 Q3	–	Sell	-23,643	Closed	-$684K	–	3248
2022 Q2	$684K	Sell	23,643 -123,826	-84%	-$3.55M	﹤0.01%	1891
2022 Q1	$4.77M	Buy	+147,469	New	+$4.52M	0.02%	972
2020 Q3	–	Sell	-18,475	Closed	-$439K	–	1586
2020 Q2	$439K	Buy	18,475 +1,759	+11%	+$38.9K	﹤0.01%	940
2020 Q1	$301K	Sell	16,716 -604	-3%	-$12.7K	﹤0.01%	991
2019 Q4	$411K	Buy	+17,320	New	+$421K	﹤0.01%	1026
2018 Q3	–	Sell	-4,024	Closed	-$241K	–	2022
2018 Q2	$241K	Sell	4,024 -1,375	-25%	-$71.2K	﹤0.01%	1585
2018 Q1	$247K	Buy	+5,399	New	+$225K	﹤0.01%	1685
2017 Q4	–	Sell	-145,625	Closed	-$5.83M	–	2299
2017 Q3	$5.83M	Buy	145,625 +140,836	+2,941%	+$6.09M	0.02%	662
2017 Q2	$206K	Buy	+4,789	New	+$170K	﹤0.01%	1377
2016 Q4	–	Sell	-110,847	Closed	-$2.74M	–	1477
2016 Q3	$2.74M	Buy	+110,847	New	+$2.51M	0.02%	586

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Balyasny Asset Management's SUPN Position: Q2 2026 in Review

Balyasny Asset Management increased its Supernus Pharmaceuticals (SUPN) stake by 1,173% in Q2 2026, buying an estimated $3.8M and bringing the position to 85,756 shares worth $3.99M. The position accounts for 0.01% of the portfolio, ranked #1478.

Balyasny Asset Management first reported a position in SUPN in Q3 2016 and has held it in 12 quarters since. The position peaked at $5.83M in Q3 2017. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Balyasny Asset Management held 85,756 shares of Supernus Pharmaceuticals worth $3.99M as of Q2 2026.
Balyasny Asset Management bought 79,018 Supernus Pharmaceuticals shares in Q2 2026, an estimated $3.8M.
Supernus Pharmaceuticals made up 0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1478 holding.
Balyasny Asset Management first reported a position in Supernus Pharmaceuticals in Q3 2016 and has held it in 12 quarters since.
Balyasny Asset Management's Supernus Pharmaceuticals position peaked at $5.83M in Q3 2017.
334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.